Ewing sarcoma of the Mandible: a systematic review and pooled survival analysis.
Oral OncolJun 16, 2026 (epub)
Clinical ResearchOncology (Medical)
Luca Canali, Andrea Costantino, Nicolò Berdin et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review analyzed 59 cases of Ewing sarcoma (ES) of the mandible, revealing that the estimated overall survival (OS) rates at 1, 3, and 5 years were 82.5%, 70.6%, and 60.9%, respectively. The study highlighted the importance of multimodal treatment, as patients receiving single-modality therapy had significantly poorer survival outcomes.
Key findings
- Estimated overall survival rates at 1, 3, and 5 years were 82.5%, 70.6%, and 60.9%, respectively.
- Pain at diagnosis was associated with significantly worse overall survival (HR 5.76, 95% CI 1.65-20.11; p = 0.01).
- Patients receiving single-modality therapy had poorer survival compared to those receiving multimodal treatment (HR 6.58, 95% CI 2.23-19.46; p < 0.005).
- Chemotherapy and surgery were associated with improved survival outcomes.
Why it matters
Understanding the clinical characteristics and survival outcomes of mandibular Ewing sarcoma is crucial for clinicians, as it informs treatment strategies and helps identify patients at higher risk of poor outcomes.